Introducing New Vaccines in Developing Countries: Concepts and Approaches to Estimating Burden of Haemophilus influenzae Type b-associated Disease

Paul E. Kilgore and Batmunkh Nyambat

Division of Translational Research, International Vaccine Institute,
PO Box 14 Kwanak, Seoul 151-600, Republic of Korea

ABSTRACT

In the past 30 years, great strides have been made in immunizing infants and children routinely in developing countries under the Expanded Programme on Immunization. Despite this, the introduction of Haemophilus influenzae type b (Hib) vaccines has progressed rather slowly compared to previously-introduced vaccines for infant immunizations. This slower uptake has been attributed partly to the need for data on the burden of invasive Hib disease. To understand this need, conceptual underpinnings and prerequisites were explored for Hib disease-burden studies. Methodological approaches were also reviewed for conducting Hib disease-burden studies that may be considered in developing countries. Potential studies span a range of designs that provide varying levels of clinical, laboratory and epidemiologic evidence of the burden of invasive Hib disease. Carefully-conducted studies can lay the foundation for complementary studies of long-term disability due to invasive Hib disease, national economic analysis, and field evaluations of vaccine. Studies done in collaboration with national agencies and clinical investigators will maximize study value and provide critical data for national decision-makers who make choices regarding the introduction of Hib vaccines.

Key words: Haemophilus influenzae; Haemophilus vaccines; Meningitis; Vaccine; Morbidity; Mortality; Epidemiology; Developing countries

INTRODUCTION

During the past several decades, a number of new vaccines have been introduced into the routine immunization programmes of developing countries starting with the earliest efforts of the World Health Organization (WHO) in the global smallpox-eradication campaign and the establishment of the Expanded Programme on Immunization (EPI) (1). During the 1970s-1980s, as developing countries introduced routine infant immunizations, there was little doubt among international health officials and national public-health decision-makers that the basic childhood vaccines, already available in developed countries for 20 or more years, were desperately needed to reduce morbidity and mortality among infants and children (2,3).

Following the development and routine introduction of new vaccines for hepatitis B and Haemophilus influenzae type b (Hib)-associated disease in developed countries, the use of these new vaccines in developing countries was felt to be a natural next step (4,5). However, the introduction of these vaccines has lagged behind their introduction in developed countries by more than 10 years (6). A number of countries still do not use hepatitis B vaccine as a routine immunization, and a good number of developing countries have yet to begin Hib immunization. In the case of hepatitis B vaccines,
a number of factors associated with delayed introduction have been identified, including problems with knowledge of disease burden, cost of vaccines, supply of vaccines, and immunization programme logistics of delivering an increasing number of vaccines to infants (7).

The experience over the past 20 years with hepatitis B and Hib vaccines has underscored the need for understanding the degree to which new vaccine-preventable diseases are a problem for a given population. This knowledge allows decision-makers to place a given disease in the overall context of national public-health problems. This process of understanding the extent of a particular disease problem requires effort to establish the burden of disease.

**BURDEN OF DISEASE**

In general, the burden of disease is represented by the sum total of outcomes that include both morbidity and mortality associated with a particular pathogen or disease (8). Thus, the burden for a number of pathogens, such as Hib, requires consideration not only of potential outcomes, e.g. hospitalizations, but recognition that Hib is capable of causing different disease manifestations (9). Thus, to account for the impact of Hib in children, we consider moderate or severe manifestations of invasive Hib disease, e.g. meningitis, pneumonia, and sepsis, that may lead to emergency visits, hospitalizations, clinical sequelae, or death (10).

Prior to the introduction of Hib vaccine in developed countries, Hib-associated deaths were frequent (11). In developing countries where access to healthcare is limited, Hib-associated mortality is thought to be high. Previous studies in several countries have shown that the highest number of Hib-associated deaths occur among children aged less than five years, especially among children aged less than two years (12,13). In addition to death, children who survive serious disease, such as Hib meningitis, are often affected by lifelong disability due to permanent damage of the central nervous system that leads to neurologic deficits (14). Such disability may lead to physical or cognitive deficits. Other severe manifestations include meningitis, pneumonia, and sepsis, and may require emergency department treatment or hospitalization.

Because of these severe disease manifestations and their associated outcomes, accurate estimation of the burden of invasive Hib disease in studies can provide important insights for health policy-makers who must make important choices regarding public-health interventions that will be financed with public or international donor funds. Appropriately-conducted burden-of-disease studies often provide previously unavailable data that show the relative importance of diseases. Results of burden-of-disease studies may also be used for projecting or modelling what might be the impact of a given vaccine when used in a routine immunization programme (15). In this way, data from baseline Hib disease-burden studies, conducted prior to the introduction of Hib vaccine, provided valuable information for later comparisons.

Since 1993, global organizations, including World Bank and WHO, have developed the concept of disability-adjusted life years (DALY) (16). DALYs are a parameter used for quantifying the burden of disease that incorporates measures of both years of life lost and years of life lived with disability. The use of DALYs is particularly useful when comparing benefits, costs, and outcomes prevented with alternative public-health programmes, such as a new vaccination programme. Estimation of DALYs associated with invasive Hib disease can incorporate information on morbidity and mortality collected in the course of Hib disease-burden studies.

Initially, one might think that disease-burden studies provide few insights into the importance that other key opinion leaders, such as clinicians, attribute to a given disease (17). However, in some cases, those who are conducting disease-burden studies often communicate with national agencies and staff who can directly use and disseminate disease-burden data. In this way, collaborative studies that involve clinicians, laboratory scientists, national public-health officers, and other national public-health workers can provide intangible benefits beyond the valuable data that such studies generate by themselves.

**CONCEPTS IN MEASURING BURDEN OF DISEASE**

**Value of disease-burden information**

Early childhood immunizations were typically introduced into routine national schedules in the absence of formal epidemiologic or clinical studies or surveillance information on the rate or number of cases of a given disease, e.g. pertussis (18,19). Why has the public-health
environment changed and why are the disease-burden data now needed? In part, this trend results from a growing number of public-health challenges that are either new, e.g. severe acute respiratory syndrome, or re-emerging diseases, e.g. tuberculosis. Another factor for lower-income countries has been the demand on the part of donor agencies that local agencies show evidence that a given disease is worthy of substantial investment (20). An additional factor may relate to the higher cost of new vaccines. The first EPI vaccines could be purchased at a substantially lower cost than new vaccines against Hib. As a result, the addition of a Hib vaccine in a national immunization programme represents a greater national financial commitment compared to previous vaccine introductions (21).

In earlier efforts to define the burden of invasive Hib disease, investigators conducted studies designed to estimate the population-based incidence of Hib and other diseases (22,23). These studies were typically conducted over a defined period to enable the calculation of annual incidence rates and used data collected either prospectively or retrospectively (24). Data from such studies have been used in conjunction with population census data for directly estimating the total number of children expected to suffer from Hib disease. Population-based studies, while often considered to provide the highest-quality data, are also more challenging due to the effort required for comprehensive case detection in large populations (25-28).

A number of Hib studies have been conducted in single hospitals or networks of hospitals over a wide geographic region (29). Such studies allow determination of the proportion of meningitis due to Hib but are less well-suited to providing estimates of Hib incidence (30,31). Nonetheless, hospital-based studies, conducted in a network of hospitals simultaneously or in a number of different hospitals over time in a given country, may provide stronger data compared to data from a single hospital-based study (32,33). Such may be the case when studies are done in ethnically- or geographically-diverse populations within a given country.

Increasingly, investigators globally are gaining experience in conducting more rigorous disease-burden studies relating to invasive Hib disease. In Africa, 26 countries initially participated in a laboratory-based surveillance system for paediatric invasive bacterial meningitis (34). In such systems, data are collected in systematic surveillance with laboratory-based testing that provides confirmed diagnoses using microbiologic culture methods. Surveillance systems such as this may provide the first and only Hib data for national decision-makers. As a result, these data may provide the foundation for later disease-burden estimates.

More recently, efforts have been made to obtain indirect estimates of burden of invasive Hib disease using retrospective reviews of hospitalizations and laboratory records of cerebrospinal fluid and blood cultures positive for Hib (35). These indirect estimates also take advantage of previous studies in which the proportion of meningitis or pneumonia due to Hib has been ascertained either through prospective laboratory-based surveillance for Hib or in Hib vaccine studies in which the proportion of pneumonia or meningitis prevented by Hib vaccine is used for estimating the proportion of disease due to Hib (36,37). This approach has led to the development of a tool to rapidly assess the burden of HIB disease (38). While still relatively new, this approach offers an alternative for countries where it is not feasible to conduct either large-scale population-based studies or sustained laboratory-based hospital studies.

Although not typically considered in the category of disease-burden studies, case reports of invasive Hib disease may be the only evidence that Hib is a cause of illness among children (39-42). While such data may be useful to local doctors when considering individual treatment decisions, they provide little evidence that Hib is more than just a sporadic disease. As such, case reports should be considered only as evidence of the presence of invasive Hib disease in a given location where it may be impossible to conduct either a rapid disease-burden assessment, hospital-based or population-based surveillance.

Local capacity for studies

Prior to initiating disease-burden studies to assess invasive Hib disease, it is crucial to evaluate the national capacity that exists to support epidemiologic surveillance and microbiologic laboratory diagnosis of Hib. If surveillance or a disease-burden study is contemplated in a province or district, attention must first be directed to understanding the ability of local clinicians and laboratory workers to identify children with bacterial meningitis (43,44). If the local capacity does not exist or exists for one aspect of surveillance, e.g. epidemiology, but does not exist for another, provisions must be established to
ensure that adequate training is conducted among workers who will be responsible for surveillance. In general, the more complex the study, e.g. population-based surveillance, the greater the need to ensure that adequately-trained personnel are in place to conduct surveillance.

The microbiologic laboratory capacity must exist or be developed prior to starting studies where investigators will use laboratory-confirmed outcomes. In many countries, the local microbiology laboratory capacity may vary greatly. Thus, in some settings, it is necessary to adapt laboratories to use less technology-intensive methods (45). In addition, investigators should have a clear documentation of local laboratory procedures before the start of formal microbiology laboratory training begins (46). Such information will be critical to design appropriate laboratory training and follow-up inspection schedules. Local laboratories must demonstrate accurate and consistent identification of invasive bacterial pathogens, including Hib, Streptococcus pneumoniae, and Neisseria meningitidis.

**Timing of disease-burden studies**

The choice of when to conduct Hib disease-burden studies may be crucial and, whenever possible, should be carefully deliberated with local and national public-health leaders. Because the capacity to conduct the surveillance of invasive Hib disease often requires clinical and/or laboratory training programmes and novel surveillance procedures for local staff, it is helpful if there are few diversions or other major public-health programmes that are initiated at the same time and in the same location where Hib surveillance is likely to take place. While this might be the ideal situation, it is not uncommon for public-health emergencies to develop that demand the involvement of local health workers who also might be involved with Hib surveillance. Similarly, other events, such as work stoppages by employees of hospitals or clinics, may also place stresses on surveillance for Hib. In other cases, conflicts may arise within communities or countries that are conducting Hib surveillance. In many situations, while it may be impossible to change the stressful circumstances having a negative impact on surveillance, development of contingency plans may be possible to mitigate the impact on surveillance and the detection of invasive Hib disease.

**Involvement of key stakeholders**

Stakeholders for Hib disease-burden studies will include individuals or groups that have an interest in data to be generated from studies on Hib. Stakeholder groups typically include donor agencies, vaccine advisory committees, paediatricians, parents, and public-health leaders within national agencies responsible for making decisions regarding the introduction of new vaccines. Thus, prior to initiating surveillance, it is valuable to know what audience will receive the Hib study data. In this way, study investigators can help ensure that results are communicated to stakeholder groups in an appropriate and timely fashion.

**APPROACHES TO BURDEN ESTIMATION**

**Measurement of outcomes**

Studies of the burden of invasive Hib disease focus on identification of children suffering from manifestations of severe disease, such as meningitis, pneumonia, and sepsis. Studies also detect children who die in hospital with confirmed Hib disease. Often, disease-burden studies will detect children who suffer clinical sequelae at the time of discharge or transfer from the hospital. Because additional effort or resources are needed to follow children several weeks or months after discharge from hospital, relatively few recent studies have described long-term clinical sequelae associated with Hib.

**Options for study design**

Choosing an appropriate design for Hib burden investigations is crucial, but resource limitations should not prevent moving forward with limited studies when there is national commitment to gaining information on invasive Hib disease (Appendix). Thus, even with limited resources, studies can be initiated to collect disease-burden data. Financial resource-limited studies should not be equated with reduced intellectual rigour or reduced efforts on the part of lead investigators to be vigilant and maintain close attention to details of conducting the study. In this sense, it may be more prudent to start small-scale studies, e.g. surveillance in a single hospital, and ensure that all children with suspected invasive Hib disease enter the surveillance system.

In the case of prospective study designs (e.g. hospital-based or population-based), an essential element of surveillance are those methods used by clinicians and epidemiologists that help ensure that all children with suspected Hib disease do, in fact, undergo evaluation within the surveillance system. If incidence rates of invasive Hib disease are expected to be low or moderately low (e.g. <10/100,000 or 10-25/100,000 children <5 years
respectively), clinicians must take great care to conduct parent/guardian interviews and physical examinations of all children who present with signs and symptoms of invasive bacterial disease. Such children must, whenever possible, undergo appropriate examinations and collection of laboratory specimens. Depending on the study duration, sufficient efforts must be expended in sustaining attention of clinician to systematic evaluation and collection of CSF, blood, or other clinical specimens.

In the case of retrospective hospital-based studies or when using the rapid disease-burden assessment, epidemiologists and laboratory workers have the greater responsibility to identify hospitals with laboratories where adequate microbiological testing has been performed over a sustained duration (47). In these studies, careful and comprehensive review of the existing computerized or paper hospital records is of paramount importance. An intimate knowledge of the laboratory operating procedures can be valuable when activities involve reviewing logbooks to identify the number of CSF or blood cultures that grow Hib. Collaboration and frequent discussions with senior microbiologists are essential to ensure that all culture results are reviewed for a given study period.

**Bias considerations**

Those conducting Hib disease-burden studies and those who use study findings may be able to anticipate characteristics of the study population, surveillance hospitals, and characteristics of the health system that could introduce potential biases that ultimately influence either the number of patients with Hib disease identified or the calculation of incidence rates, or both. These biases may result from inadequate consideration of healthcare-seeking behaviours or healthcare institutions where parents bring children for care of serious or life-threatening diseases. They may also stem from inadequate knowledge of study clinicians regarding the signs and symptoms of disease that require prompt medical attention, evaluation, and collection of laboratory specimens. Other biases may include partial or complete absence of patient referral whereby local doctors, e.g. private clinics, choose to evaluate and treat patients with suspected invasive Hib disease rather than to participate in surveillance by referring patients to a nearby hospital where CSF and/or blood can be collected for microbiologic culture. Other potential sources of bias may limit the detection of fastidious Hib organisms when specimens are not transported or processed within a relatively short time.

**Analysis**

Plans for analysis of surveillance data may be easily overlooked when one is in the planning stages or early phases of surveillance. However, establishing an analytic strategy is essential to ensure that appropriate data are collected and that weekly or monthly reviews of data are focused on ensuring that complete and accurate data are recorded. Incomplete data discovered at the end of a study or surveillance period may preclude analysis of valuable data on one or more key outcome(s) for the disease-burden study. Time must be taken to plan how data will be presented in both periodic interim reports and the final report. If appropriate to the study design, methods for the calculation of incidence rates of invasive Hib disease should be described and understood by study investigators. Increasingly, performance indicators are being used in surveillance and disease-burden studies. Such indicators help monitor the progress of data collection and the quality of surveillance activities. Statistical comparisons of surveillance indicators from month to month provide valuable feedback to clinicians, laboratory workers, and epidemiologists who perform day-to-day surveillance activities.

**Integration of outcome studies**

National leaders with responsibility for decision-making may view invasive Hib disease from different perspectives. Some may value the calculation of incidence rates and the fact that these can be used for estimating the annual number of expected patients with invasive Hib disease. Some may value the fact that studies yield credible data on the number of children who may die as a result of invasive Hib disease or the case-fatality rate among children with serious Hib disease. Other decision-makers may wish to know the proportion of children who suffer long-term or even lifelong disability due to invasive Hib disease. Finally, other decision-makers may wish to compare the burden of invasive Hib disease based on DALYs (48). Such diverse needs can be met by anticipating that study results from different time periods, populations, or that were derived from different methods should be integrated into a package of Hib-burden information that is easily digested by national decision-makers with or without a clinical or laboratory background.

**Reporting study results**

In the planning stages of a burden study, simple tabulations and sample figures can be created to illustrate
how data will be reported. Reports should be brief and written in a relatively simple language to allow understanding by readers with varying backgrounds. Outcomes of epidemiologic studies, e.g. incidence rates, can be 'translated' into a simpler language to maximize understanding among readers. One approach that may be used involves showing the risk of disease in terms of percentage risk (e.g. x children out of every 10) or may convert risk into language where the risk of a given outcome is placed in terms that use a "lowest common denominator" (e.g. 1 child in every 8 will develop Hib disease). Finally, in using these simpler approaches to quantifying outcomes of Hib-burden study, it is useful to consider quantifying risk over a defined period or age group (e.g. 1 in every 20 children will be hospitalized for Hib disease each year). Alternatively, investigators may express the outcome as a cumulative risk of an outcome event (e.g. 1 in every 8 children will develop Hib disease by the age of 5 years).

**IMPLICATIONS OF HIB-BURDEN STUDIES**

**Economic analyses**

Hib disease-burden studies provide data that can be critical for sound economic analysis of Hib-prevention programmes. Data inputs with respect to Hib-associated disease-incidence rates, mortality rates, case-fatality, and the occurrence of clinical sequelae may come from a number of different sources, including published scientific articles, government reports, or personal communications from experts in the field. The quality of data used in economic analysis of Hib-prevention programmes is also important to understand and consider prior to initiating economic studies. Thus, one rationale for conducting high-quality Hib disease-burden studies is that they can provide data for use in making optimal cost-effectiveness or cost-benefit calculations for Hib disease-prevention programmes.

**Evaluation of vaccine**

Evaluation of Hib vaccine in the context of a large-scale vaccine-demonstration project is often considered to address policy uncertainties (49). Evaluation of Hib conjugate vaccines (vaccine-effectiveness studies or so-called vaccine 'probe' studies) following the introduction of vaccine may also be considered to evaluate the programmatic impact of Hib immunization (50). In the latter case, national health agencies may have ongoing active surveillance systems in which laboratory-confirmed Hib disease is identified (51). As such, disease-burden studies in which active or passive surveillance is conducted for laboratory-confirmed Hib-associated disease can take on added value when such systems are used for evaluating the impact of Hib immunization as Hib vaccine uptake increases (52,53). In other cases, passive reporting of Hib-associated cases is used for estimating the population impact of Hib immunization over a defined period (54). In still other situations, infants may be randomized by group or individual to receive Hib vaccine or another vaccine while all children are monitored in ongoing surveillance for Hib-associated disease (55,56). Hib disease-burden data, e.g. cases of meningitis, can also be evaluated retrospectively or prospectively to evaluate the impact of Hib immunization (57). In this study design, cases may be matched with controls to compare those children who received Hib vaccine with those who did not receive Hib vaccine (58-60).

**Post-introduction surveillance**

If the introduction of Hib vaccines is planned, the burden of Hib can be monitored as noted above to evaluate the impact of vaccine, reduction in incidence of disease, and Hib vaccine-related adverse events (61). Adverse events following any vaccine are of critical importance to immunization programmes, and adverse events, including breakthrough disease, can be monitored following the administration of Hib vaccine. Surveillance of adverse events may be conducted with passive or active reporting of events (62). Most reporting systems monitor events passively, and such events can be tabulated periodically to estimate the burden of these events.

**CONCLUSION**

The introduction of Hib vaccines in developing countries is currently limited by a number of factors. Prominent among these are limited evidence that invasive Hib disease is a problem of sufficient importance to warrant investment in vaccination programmes. While the first childhood vaccines were introduced without systematic disease-burden studies, contemporary national policy-makers and international donors must often consider the need for Hib vaccine against competing priorities. In this scenario, disease-burden studies also become valuable as tools to provide data for economic studies and vaccine-evaluation projects and to build infrastructure for post-introduction evaluation of the impact of vaccine. While disease-burden studies
have increased in sophistication in recent years, practical limitations must be addressed to design studies that are feasible and that provide credible evidence. While population-based studies may be considered, alternative study designs, such as hospital-based studies or vaccine probe studies, may provide useful evidence to guide policy-makers especially when combined with studies of long-term sequelae and economic analysis.

ACKNOWLEDGEMENTS
We thank Min Kyoung Oh for her assistance in the preparation of this manuscript.

REFERENCES


New vaccines in developing countries


### Appendix

**Options of study design for Hib disease-burden studies in developing countries**

<table>
<thead>
<tr>
<th>Option of study design</th>
<th>Reference no.</th>
<th>Outcomes for analysis</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case report</td>
<td>63</td>
<td>Not applicable</td>
<td>Ease of investigation; fast reporting</td>
<td>Not representative; no comparative information on different pathogens or manifestations of disease</td>
</tr>
<tr>
<td>Case series</td>
<td>64</td>
<td>Proportion and number of cases due to Hib, other pathogens</td>
<td>Usually involves one hospital; easier logistics; often retrospective, non-systematic data collection</td>
<td>Sometimes limited to manifestation of one disease or one pathogen</td>
</tr>
<tr>
<td>Single hospital study</td>
<td>65</td>
<td>Proportion and number of cases due to Hib, other pathogens</td>
<td>Usually involves one hospital; easier logistics; more systematic data collection, may be prospective</td>
<td>May not be population-based; may not be representative</td>
</tr>
<tr>
<td>Local or national surveillance or administrative databases</td>
<td>66,67</td>
<td>Number of hospitalizations or deaths due to bacterial meningitis or incidence of Hib meningitis and/or mortality rates due to Hib disease</td>
<td>Data may be accessible in computerized format; often captures more severe outcomes</td>
<td>May not be representative of entire population if under-reporting present; may not include less severe outcomes</td>
</tr>
<tr>
<td>Rapid Hib disease-burden assessment (RAT)</td>
<td>35</td>
<td>Cases (incidence) and deaths (mortality) due to Hib meningitis and pneumonia</td>
<td>Faster than hospital- or population-based studies</td>
<td>Not direct incidence estimate Depends on assumptions from scant literature</td>
</tr>
<tr>
<td>Hospital network</td>
<td>32</td>
<td>Cases and deaths due to manifestations of severe Hib disease (meningitis, pneumonia, sepsis)</td>
<td>Logistically easier than population-based study</td>
<td>More difficult to estimate incidence</td>
</tr>
<tr>
<td>Population-based study</td>
<td></td>
<td>Cases and deaths due to manifestations of severe Hib disease (meningitis, pneumonia, sepsis)</td>
<td>Allows incidence calculation</td>
<td>Logistically difficult; resource-intensive May require training and capacity-strengthening for laboratory</td>
</tr>
<tr>
<td>Case-control study</td>
<td>59</td>
<td>Hib vaccine effectiveness Attributable fraction of disease manifestation (e.g. meningitis) due to Hib Indirect Hib incidence estimate</td>
<td>Provides estimate of Hib vaccine effectiveness Less resource-intensive compared to cluster randomized effectiveness trial</td>
<td>Moderately expensive Potentially subject to bias</td>
</tr>
<tr>
<td>Vaccine 'probe' study</td>
<td>50</td>
<td>Hib vaccine effectiveness Attributable fraction of manifestation of disease (e.g. meningitis) due to Hib Indirect Hib incidence estimate</td>
<td>Gives vaccine effectiveness Methodologically rigorous Less subject to bias</td>
<td>Expensive Requirement of a larger sample size Complicated Indirect incidence estimate</td>
</tr>
</tbody>
</table>